Skip Nav Destination
Issues
1 June 2009
-
Cover Image
Cover Image
Immunohistochemical staining of pancreatic cancer tissues with nerve invasion of cancer cells using a KIF14-specific antibody. Note the weak to absent KIF14 expression in the cancer cells and the positive staining (brown) in the nerve tissue. For details, see Abiatari et al., in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Issue Sections
Minireview
Research Articles
Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors
Richard D. Baird; Jos Kitzen; Paul A. Clarke; Andre Planting; Sarah Reade; Alison Reid; Lyndsey Welsh; Luis López Lázaro; Begona de las Heras; Ian R. Judson; Stan B. Kaye; Ferry Eskens; Paul Workman; Johann S. deBono; Jaap Verweij
Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts
Wells A. Messersmith; N.V. Rajeshkumar; Aik Choon Tan; Xiao Fei Wang; Veronica Diesl; Sung E. Choe; Max Follettie; Christina Coughlin; Frank Boschelli; Elena Garcia-Garcia; Fernando Lopez-Rios; Antonio Jimeno; Manuel Hidalgo
Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells
Dmitri V. Rozanov; Alexei Y. Savinov; Vladislav S. Golubkov; Olga L. Rozanova; Tatiana I. Postnova; Eduard A. Sergienko; Stefan Vasile; Alexander E. Aleshin; Michele F. Rega; Maurizio Pellecchia; Alex Y. Strongin
Simultaneous blockade of the epidermal growth factor receptor/mammalian target of rapamycin pathway by epidermal growth factor receptor inhibitors and rapamycin results in reduced cell growth and survival in biliary tract cancer cells
Beata Herberger; Walter Berger; Harald Puhalla; Katharina Schmid; Sabine Novak; Anita Brandstetter; Christine Pirker; Thomas Gruenberger; Martin Filipits
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds